The U.S. Food and Drug Administration today approved bevacizumab-awwb (Mvasi) as a biosimilar to bevacizumab (Avastin) for the treatment of multiple types of cancer. Bevacizumab-awwb is the first biosimilar approved in the U.S. for the treatment of cancer.
This year, for the first time, a live, local and interactive event took place in Belgium simultaneously with the ASCO® Annual Meeting in Chicago. During this two-day meeting, Belgian oncologists were informed about the most important and interesting developments in oncology presented at the ASCO Annual Meeting.
The yearly Pfizer Oncology Award is worth € 25.000 and is intended to support, recognise and encourage one innovative project in Belgium or Luxembourg that improves the quality and/or availability of patient care in oncology. The Pfizer Oncology Award is open to any project related to the clinical, surgical and medical or technical aspects of patient care in oncology, but also to different ways of collaboration and/or organisation between various health care providers or between levels of care during the course of the disease.
This educational course on medical oncology is organised by top academic experts in the field of medical oncology in synergy with the ESMO Young Oncologists Committee.
Phase III APHINITY Study showed a statistically significant improvement in invasive disease-free survival (iDFS) for people with HER2-positive early breast cancer (EBC) compared to Herceptin and chemotherapy alone
Please see the section BSMO Annual Meetings for all information.
All information on the Postgraduate Courses Medical Oncology 2017 is available at the dedicated section of the BSMO website. Please click here for information.
FDA Grants Accelerated Approval to Nivolumab in Classical Hodgkin Lymphoma
On April 25, 2016, the U. S. Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.